搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
The Pharma Letter
2 小时
Servier appoints David Lee to executive committee
French independent pharma company Servier says it has appointed David Lee to its executive committee as executive vice ...
The Pharma Letter
4 小时
Lantheus to acquire Life Molecular Imaging
US radiopharmaceuticals-focused Lantheus Holdings today announced a definitive agreement to acquire Life Molecular Imaging.
The Pharma Letter
3 小时
Mediar Therapeutics inks IPF deal with Lilly
US fibrosis-focused drug developer Mediar Therapeutics has entered into global licensing agreement with US pharma major Eli ...
The Pharma Letter
3 小时
MDC brings in CCO and MD
Medicines Discovery Catapult (MDC), the UK government-backed life sciences service dedicated to driving productivity and ...
The Pharma Letter
3 小时
Ouro Medicines debuts with $120 million financing
California-based immunology start-up Ouro Medicines, which is developing immune reset therapeutics for people living with ...
The Pharma Letter
5 小时
J&J punts $14.6 billion on buy of Intra-Cellular Therapies
Shares of USA-based Intra-Cellular Therapies leapt almost 36% to $128.85 in pre-marker activity today, as rumors of a ...
The Pharma Letter
6 小时
CNX and Klaria tee up European launch for new migraine drug
CNX Therapeutics partners with Klaria Pharma to market sumatriptan alginate film in Europe, addressing critical migraine ...
The Pharma Letter
6 小时
Aragen gains $100 million investment from Quadria
Aragen Life Sciences secures $100M investment from Quadria Capital, valuing the CRDMO at $1.4B. The funding supports ...
The Pharma Letter
5 小时
GSK takes aim at GIST with $1 billion IDRx buy
UK pharma major GSK is to acquire IDRx, a Boston, USA-based, clinical-stage biopharma developing precision therapeutics for ...
The Pharma Letter
7 小时
First stem cell therapy, new HIV drug approved in China
China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication ...
The Pharma Letter
8 小时
AbbVie takes $3.5 billion hit after schizophrenia failure
AbbVie records a $3.5 billion impairment charge following the failure of emraclidine in Phase II schizophrenia trials.
The Pharma Letter
8 小时
Merus and Biohaven link up on ADC programs
US biopharma Biohaven and Dutch biotech Merus have announced a research collaboration and license agreement to co-develop ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈